Literature DB >> 25560639

Expression of claudins in human clear cell renal cell carcinoma.

Wenjin Men1, Tracey A Martin2, Fiona Ruge2, Ning Zhang3, Peng DU4, Yong Yang4, Wen G Jiang2.   

Abstract

The current study investigated the expression of claudins 1, 5 and 16 in human clear cell renal cell carcinoma (CCRCC) and the impact of claudin-16 on kidney cancer cells. Levels of claudin transcripts were assessed using quantitative reverse transcription-polymerase reaction and proteins were examined by immunohistochemical methods. Human kidney epithelial cell HEK293 and human kidney cancer cell line UMRC2 were also used in the study. Human kidney tissues expressed high levels of claudin-1 and in particular claudin-16, but were negative for claudin-5. Late-stage kidney carcinomas tended to express low levels of claudin-1 and claudin-16. UMRC2 cells, highly positive for claudin-16, were transfected with an anti-claudin-16 transgene, which resulted in significant reduction in both transepithelial resistance and cell matrix adhesion compared to control cells. When HEK293 cells, negative for expression of claudin-16, were forced to express claudin-16, the cells showed a marked increase in transepithelial resistance and to some degree in cell matrix adhesion. In conclusion, the present study showed that kidney tissue and CCRCC tissues highly expressed claudin-16 and claudin-1, and that claudin-16 has a profound impact on barrier function and cell adhesion in kidney cancer cells. Copyright
© 2015, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.

Entities:  

Keywords:  Claudin-1; claudin-16; claudin-5; clear cell renal cell carcinoma; paracellular permeability

Mesh:

Substances:

Year:  2015        PMID: 25560639

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  7 in total

Review 1.  Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.

Authors:  Marina O Golovastova; Dmitry O Korolev; Larisa V Tsoy; Vladimir A Varshavsky; Wan-Hai Xu; Andrey Z Vinarov; Evgeni Yu Zernii; Pavel P Philippov; Andrey A Zamyatnin
Journal:  Curr Urol Rep       Date:  2017-01       Impact factor: 3.092

Review 2.  Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis.

Authors:  Astrid O Leech; Rodrigo G B Cruz; Arnold D K Hill; Ann M Hopkins
Journal:  Ann Transl Med       Date:  2015-08

Review 3.  Claudins as biomarkers of differential diagnosis and prognosis of tumors.

Authors:  Olga P Popova; Alla V Kuznetsova; Svetlana Yu Bogomazova; Alexey A Ivanov
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-09       Impact factor: 4.553

Review 4.  Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk.

Authors:  Ajaz A Bhat; Srijayaprakash Uppada; Iman W Achkar; Sheema Hashem; Santosh K Yadav; Muralitharan Shanmugakonar; Hamda A Al-Naemi; Mohammad Haris; Shahab Uddin
Journal:  Front Physiol       Date:  2019-01-23       Impact factor: 4.566

Review 5.  Tight junction proteins in gastrointestinal and liver disease.

Authors:  Mirjam B Zeisel; Punita Dhawan; Thomas F Baumert
Journal:  Gut       Date:  2018-10-08       Impact factor: 31.793

Review 6.  Accessory proteins for heterotrimeric G-proteins in the kidney.

Authors:  Frank Park
Journal:  Front Physiol       Date:  2015-08-07       Impact factor: 4.566

7.  Role of Nuclear Claudin-4 in Renal Cell Carcinoma.

Authors:  Takuya Owari; Takamitsu Sasaki; Kiyomu Fujii; Rina Fujiwara-Tani; Shingo Kishi; Shiori Mori; Takuya Mori; Kei Goto; Isao Kawahara; Yasushi Nakai; Makito Miyake; Yi Luo; Nobumichi Tanaka; Masuo Kondoh; Kiyohide Fujimoto; Hiroki Kuniyasu
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.